The cost of Fostair1
*Cost per 30 days of treatment.1
30 day acquisition costs of ICS/LABA combination inhalers based on list price – COPD
This graph does not imply clinical comparability
30 day cost comparison1
*Fostair pMDI and NEXThaler 100/6 are licensed for patients with severe COPD (FEV1 <50% predicted). Full licensed indication can be found in the Prescribing Information.
ICS: Inhaled corticosteroid; LABA: Long-acting β2-agonist.
O.D.: Once daily; B.D.: Twice daily.
Seretide®, Accuhaler®, Relvar® and Ellipta® are registered trademarks of the GlaxoSmithKline Group of Companies. AirFluSal® and Forspiro® are registered trademarks of Sandoz Limited. Symbicort® and Turbohaler® are registered trademarks of AstraZeneca AB Limited. DuoResp® and Spiromax® are registered trademarks of Teva Pharmaceuticals Europe and are used under licence. Fobumix® and Easyhaler® are registered trademarks of Orion Pharma UK Limited. Fusacomb® is a registered trademark of Orion Corporation. Stalpex® is a registered trademark of Glenmark Pharmaceuticals Europe Limited.
Prices correct as of February 2020.
UK-FTB-2000007 Feb 2020
1.MIMS Online. Available from: www.mims.co.uk Accessed February 2020.